OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology

OSE Immunotherapeutics SA presented two additional posters reporting the latest research updates on CLEC-1, from its Myeloid platform, at the 2023 American Association for Cancer Research Annual Meeting held in Orlando on April 14-19.

Scroll to Top